{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:14:33Z","timestamp":1783617273492,"version":"3.55.0"},"reference-count":92,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Opioids are frequently prescribed for cancer pain management, yet accumulating evidence suggests that opioid exposure may be associated with inferior outcomes in patients also undergoing treatment with immune checkpoint inhibitors (ICIs). To synthesize mechanistic and clinical evidence linking opioids to the PD-1\/PD-L1 axis, the literature was searched up to 18 January 2026, with study selection and data extraction focused on (i) cancer-cell and immune-cell effects of opioid agonism or antagonism on PD-1\/PD-L1 biology, and (ii) clinical studies reporting ICI outcomes (progression-free survival, overall survival, or treatment duration) with concomitant opioid exposure. Preclinical studies support multiple, non-mutually exclusive mechanisms: opioids can induce PD-L1 in tumour cells, modulate innate-inflammatory pathways (including TLR4-linked cascades), promote dysfunctional T-cell phenotypes that reduce responsiveness to PD-1 blockade, and show context- and opioid-dependent effects. Clinical cohorts and meta-analytic datasets in non-small cell lung cancer and other tumour types report associations between opioid exposure (including higher morphine-equivalent dosing) and worse ICI outcomes. The intersection of opioid signaling with PD-1\/PD-L1 biology likely operates across cancer cell-intrinsic and immune cell-intrinsic pathways, providing a mechanistic rationale for prospective evaluation of opioid-sparing strategies and\/or peripheral opioid antagonism as adjuncts to checkpoint blockade.<\/jats:p>","DOI":"10.3390\/curroncol33070411","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:16:44Z","timestamp":1783613804000},"page":"411","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Crosstalk Between Opioids and the Anti-Tumour Immune Checkpoint Axis"],"prefix":"10.3390","volume":"33","author":[{"given":"Parsa","family":"Alan","sequence":"first","affiliation":[{"name":"Faculty of Medicine, The University of Queensland, Brisbane, QLD 4029, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-7381","authenticated-orcid":false,"given":"Marie-Odile","family":"Parat","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, Brisbane, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: Updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-024-00700-2","article-title":"Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back","volume":"39","author":"Mariniello","year":"2025","journal-title":"BioDrugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-024-02179-5","article-title":"Current trends in sensitizing immune checkpoint inhibitors for cancer treatment","volume":"23","author":"Wei","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: The randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2020.07.004","article-title":"Clinical Challenges of Immune Checkpoint Inhibitors","volume":"38","author":"Calvo","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"ii119","DOI":"10.1093\/annonc\/mdn108","article-title":"Management of cancer pain: ESMO Clinical Recommendations","volume":"19","author":"Jost","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00726-011-1163-0","article-title":"Role of the mu-opioid receptor in opioid modulation of immune function","volume":"45","author":"Roy","year":"2013","journal-title":"Amino Acids"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S713","DOI":"10.1016\/j.jtho.2019.08.1520","article-title":"P2.04-15 Association Between Opioids and Outcome of 1st Line Immunotherapy in Advanced NSCLC Patients: A Retrospective Evaluation","volume":"14","author":"Bironzo","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e001361","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"23331","DOI":"10.1038\/s41598-021-02598-0","article-title":"The association between gut microbiome affecting concomitant medication and the effectiveness of immunotherapy in patients with stage IV NSCLC","volume":"11","author":"Verschueren","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12967-021-02784-8","article-title":"The role of opioids in cancer response to immunotherapy","volume":"19","author":"Botticelli","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1111\/1759-7714.14001","article-title":"Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study","volume":"12","author":"Miura","year":"2021","journal-title":"Thorac. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejca.2021.08.036","article-title":"Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events","volume":"157","author":"Kostine","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yu, X., Zhao, L., and Song, B. (2022). Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population. BMC Pulm. Med., 22.","DOI":"10.1186\/s12890-022-02210-9"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1136\/bmjspcare-2020-002480","article-title":"Opioids impair nivolumab outcomes: A retrospective propensity score analysis in non-small-cell lung cancer","volume":"13","author":"Taniguchi","year":"2023","journal-title":"BMJ Support. Palliat. Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"106363","DOI":"10.1016\/j.oraloncology.2023.106363","article-title":"The effect of opioids on the efficacy of immunotherapy in recurrent\/metastatic squamous cell carcinoma of the head and neck","volume":"140","author":"Scheff","year":"2023","journal-title":"Oral Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"111611","DOI":"10.1016\/j.intimp.2024.111611","article-title":"A novel investigation into the negative impact of opioid use on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients","volume":"129","author":"Guo","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/curroncol31010017","article-title":"Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors","volume":"31","author":"Young","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.62347\/VHDF3303","article-title":"Are they all the same? Different effects of opioid types on survival in metastatic NSCLC receiving nivolumab","volume":"15","author":"Urvay","year":"2025","journal-title":"Am. J. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e010311","DOI":"10.1136\/jitc-2024-010311","article-title":"Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types","volume":"13","author":"Gandara","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"30267","DOI":"10.1038\/s41598-025-15684-4","article-title":"Association between opioid use and survival in advanced non small cell lung cancer patients treated with immune checkpoint inhibitors","volume":"15","author":"Liguori","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/ijc.70009","article-title":"Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population","volume":"157","author":"Prinzi","year":"2025","journal-title":"Int. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12967-025-07570-4","article-title":"Salivary microbial signature highlighting actinomyces as a predictor of immune-checkpoint inhibitor monotherapy response in advanced non\u2013small cell lung cancer","volume":"24","author":"Cavaliere","year":"2026","journal-title":"J. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e70222","DOI":"10.1002\/cncr.70222","article-title":"The effect of common medications on the efficacy of immune checkpoint inhibitors","volume":"131","author":"Brinzevich","year":"2025","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Tsuboi, I., Matsukawa, A., Parizi, M.K., Miszczyk, M., Fazekas, T., Schulz, R.J., Laukhtina, E., Kawada, T., Katayama, S., and Iwata, T. (2025). Impact of concomitant medications on the oncologic efficacy of systemic therapy in patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. BMC Urol., 25.","DOI":"10.1186\/s12894-025-01754-2"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jtho.2020.10.060","article-title":"MO01.12 Association of Opioid Use with Survival in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitor Therapy","volume":"16","author":"Mock","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Mao, Z., Jia, X., Jiang, P., Wang, Q., Zhang, Y., Li, Y., Fu, X., Jiao, M., Jiang, L., and Liu, Z. (2022). Effect of Concomitant Use of Analgesics on Prognosis in Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.861723"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00432-024-05728-z","article-title":"Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: Analysis of Health Insurance Review and Assessment data","volume":"150","author":"Hong","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"115560","DOI":"10.1016\/j.ejca.2025.115560","article-title":"Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS","volume":"225","author":"Gobbini","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s12094-019-02282-w","article-title":"Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer","volume":"22","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"17588359211000591","DOI":"10.1177\/17588359211000591","article-title":"Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors","volume":"13","author":"Gaucher","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_36","first-page":"346.e1","article-title":"Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors","volume":"40","author":"Fukuokaya","year":"2022","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e14564","DOI":"10.1200\/JCO.2022.40.16_suppl.e14564","article-title":"Inferior survival outcomes with concomitant immune checkpoint inhibitors and chronic opioid use","volume":"40","author":"Varghese","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e14595","DOI":"10.1200\/JCO.2022.40.16_suppl.e14595","article-title":"Association of opioid use with response to immune checkpoint inhibitors","volume":"40","author":"Weinfeld","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1038\/s41598-024-53158-1","article-title":"Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma","volume":"14","author":"Iida","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_40","first-page":"467","article-title":"Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors","volume":"32","author":"Kavgaci","year":"2024","journal-title":"Support. Care Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1007\/s12029-024-01095-7","article-title":"Concomitant Medications Alter Clinical Outcomes in Patients with Advanced Digestive Tract Cancer Receiving PD-1 Checkpoint Inhibitors Combined with Antiangiogenetic Agents","volume":"55","author":"Wang","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.bja.2025.02.030","article-title":"Effects of opioids on tumour growth and metastasis in animal models: A systematic review","volume":"134","author":"Welch","year":"2025","journal-title":"Br. J. Anaesth."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1111\/bph.13903","article-title":"Influence of opioids on immune function in patients with cancer pain: From bench to bedside","volume":"175","author":"Boland","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/bjc.2014.384","article-title":"Effects of opioids on immunologic parameters that are relevant to anti-tumour immune potential in patients with cancer: A systematic literature review","volume":"111","author":"Boland","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/s41416-022-01928-x","article-title":"Possible mechanism for improving the endogenous immune system through the blockade of peripheral \u03bc-opioid receptors by treatment with naldemedine","volume":"127","author":"Gondoh","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Wang, Q., Liu, Z., Tang, S., and Wu, Z. (2022). Morphine suppresses the immune function of lung cancer by up-regulating MAEL expression. BMC Pharmacol. Toxicol., 23.","DOI":"10.1186\/s40360-022-00632-z"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"107999","DOI":"10.1016\/j.intimp.2021.107999","article-title":"A novel mechanism of lung cancer inhibition by methionine enkephalin through remodeling the immune status of the tumor microenvironment","volume":"99","author":"Zhang","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"107837","DOI":"10.1016\/j.intimp.2021.107837","article-title":"Methionine enkephalin (MENK) suppresses lung cancer by regulating the Bcl-2\/Bax\/caspase-3 signaling pathway and enhancing natural killer cell-driven tumor immunity","volume":"98","author":"Zhang","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.intimp.2018.09.040","article-title":"Rules to activate CD8+T cells through regulating subunits of opioid receptors by methionine enkephalin (MENK)","volume":"65","author":"Jiao","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.20892\/j.issn.2095-3941.2020.0442","article-title":"Morphine-3-glucuronide upregulates PD-L1 expression via TLR4 and promotes the immune escape of non-small cell lung cancer","volume":"18","author":"Wang","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"14466","DOI":"10.1038\/s41598-023-41325-9","article-title":"Structure based virtual screening and molecular simulation study of FDA-approved drugs to inhibit human HDAC6 and VISTA as dual cancer immunotherapy","volume":"13","author":"Shahab","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Min, X., Ma, Y., Lv, M., Li, X., Lv, R., Zhao, X., and Leng, Y. (2025). Exploring the possible mechanism of low-dose naloxone exposure improving the immune microenvironment of gastric cancer tumors. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1524930"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"109125","DOI":"10.1016\/j.intimp.2022.109125","article-title":"Methionine enkephalin inhibits colorectal cancer by remodeling the immune status of the tumor microenvironment","volume":"111","author":"Wang","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e009962","DOI":"10.1136\/jitc-2024-009962","article-title":"Morphine treatment restricts response to immunotherapy in oral squamous cell carcinoma","volume":"12","author":"McIlvried","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Scarpa, J.R., Montagna, G., Plitas, G., Gulati, A., Fischer, G.W., and Mincer, J.S. (2023). Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1267532"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Sun, W., Zhuang, S., Cheng, M., and Qiu, Z. (2023). Mu opioid receptor mRNA overexpression predicts poor prognosis among 18 common solid cancers: A pan-cancer analysis. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1134744"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.2147\/IJGM.S434076","article-title":"Pan-Cancer Analysis and Validation of Opioid-Related Receptors Reveals the Immunotherapeutic Value of Toll-Like Receptor 4","volume":"16","author":"Wu","year":"2023","journal-title":"Int. J. Gen. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"11389","DOI":"10.1038\/srep11389","article-title":"Morphine Modulates Interleukin-4- or Breast Cancer Cell-induced Pro-metastatic Activation of Macrophages","volume":"5","author":"Khabbazi","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Khabbazi, S., Xie, N., Pu, W., Goumon, Y., and Parat, M.-O. (2016). The TLR4-Active Morphine Metabolite Morphine-3-Glucuronide Does Not Elicit Macrophage Classical Activation In Vitro. Front. Pharmacol., 7.","DOI":"10.3389\/fphar.2016.00441"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Liu, W., Ou, C., Xue, R., Yang, X., Ye, Y., Wang, X., and Xie, J. (2024). Opioid-free anesthesia attenuates perioperative immunosuppression by regulating macrophages polarization in gastric cancer patients treated with neoadjuvant PD-1 inhibitor. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1438859"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"10732748261430581","DOI":"10.1177\/10732748261430581","article-title":"Research Progress on Tumor-Associated Macrophages and PD-1\/PD-L1 Inhibitors in Advanced Colorectal Cancer","volume":"33","author":"Ning","year":"2026","journal-title":"Cancer Control"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Pu, Y., and Ji, Q. (2022). Tumor-Associated Macrophages Regulate PD-1\/PD-L1 Immunosuppression. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.874589"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"173253","DOI":"10.1016\/j.ejphar.2020.173253","article-title":"The paradoxical role of methionine enkephalin in tumor responses","volume":"882","author":"Tuo","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Gabr, M.M., Saeed, I., Miles, J.A., Ross, B.P., Shaw, P.N., Hollmann, M.W., and Parat, M.-O. (2021). Interaction of Opioids with TLR4\u2014Mechanisms and Ramifications. Cancers, 13.","DOI":"10.3390\/cancers13215274"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Scroope, C.A., Singleton, Z., Hollmann, M.W., and Parat, M.-O. (2021). Opioid Receptor-Mediated and Non-Opioid Receptor-Mediated Roles of Opioids in Tumour Growth and Metastasis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.792290"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Lei, Y., Cao, C., Tang, R., and Liu, Y. (2025). Peripheral blood inflammatory biomarkers neutrophil\/ lymphocyte ratio, platelet\/lymphocyte ratio and systemic immune-inflammation index\/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opioids. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14060-9"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jpain.2023.02.002","article-title":"PD-1: A New Candidate Target for Analgesic Peptide Design","volume":"24","author":"Zhao","year":"2023","journal-title":"J. Pain"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"eaaw6471","DOI":"10.1126\/scitranslmed.aaw6471","article-title":"Anti-PD-1 treatment impairs opioid antinociception in rodents and nonhuman primates","volume":"12","author":"Wang","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1021\/acschemneuro.4c00732","article-title":"Enhanced Analgesic Efficacy and Reduced Side Effects of Morphine by Combination with PD-1 Agonist","volume":"16","author":"Song","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"101570","DOI":"10.1016\/j.isci.2020.101570","article-title":"PD-1 Regulates GABAergic Neurotransmission and GABA-Mediated Analgesia and Anesthesia","volume":"23","author":"Jiang","year":"2020","journal-title":"iScience"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1248\/bpb.b25-00515","article-title":"A Multicenter Retrospective Observational Study on Drug-Drug Interactions between Opioid Analgesics and Immune Checkpoint Inhibitors in Cancer Patients","volume":"48","author":"Miyasato","year":"2025","journal-title":"Biol. Pharm. Bull."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e14893","DOI":"10.1111\/cns.14893","article-title":"Increased opioid consumption in neoadjuvant immunotherapy plus chemotherapy for patients with non-small-cell lung cancer: A multicenter, prospective cohort study","volume":"30","author":"Wang","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"19121","DOI":"10.1038\/s41598-026-49512-0","article-title":"Effects of preoperative anti-PD-1 therapy on intraoperative and postoperative analgesia in patients undergoing radical esophagectomy: A retrospective cohort study","volume":"16","author":"Yang","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ejp.2056","article-title":"Lung cancer patients with positive programmed death-ligand 1 expression endure graver postoperative pain","volume":"27","author":"Wang","year":"2023","journal-title":"Eur. J. Pain"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/jcpt.13541","article-title":"Exacerbation of cancer pain after administering immune checkpoint inhibitor in a patient taking opioids: A case report","volume":"47","author":"Sumimoto","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMc1815143","article-title":"More on Mu-Opioid Receptor Antagonists in PD-1 Blockade-Induced Pruritus","volume":"380","author":"Kwatra","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMc1805637","article-title":"PD-1 Blockade-Induced Pruritus Treated with a Mu-Opioid Receptor Antagonist","volume":"379","author":"Kwatra","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/mi.2016.9","article-title":"Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation","volume":"9","author":"Banerjee","year":"2016","journal-title":"Mucosal Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/apt.13858","article-title":"Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis","volume":"45","author":"Acharya","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Kim, W., Cho, Y.-A., Kim, D.-C., Jo, A.-R., Min, K.-H., and Lee, K.-E. (2021). Factors Associated with Thyroid-Related Adverse Events in Patients Receiving PD-1 or PD-L1 Inhibitors Using Machine Learning Models. Cancers, 13.","DOI":"10.3390\/cancers13215465"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e948143","DOI":"10.12659\/AJCR.948143","article-title":"Hypophysitis Induced by Tislelizumab: A Case Report of Somnolence and Delirium with Elevated Eosinophils","volume":"26","author":"Hu","year":"2025","journal-title":"Am. J. Case Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1177\/02692163211001295","article-title":"Immunotherapy associated pain crisis and the haemophagocytic lymphohistiocytosis syndrome in advanced melanoma: Case report and review of the literature","volume":"35","author":"Krasovitsky","year":"2021","journal-title":"Palliat. Med."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Baldeo, R., Rosa, W.E., Ellis-Wittenhagen, J., and Wordingham, S.E. (2025). Immune Checkpoint Inhibitor Mediated Keratitis: A Case Study. J. Palliat. Med.","DOI":"10.1177\/10966218251392777"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/08923973.2024.2430670","article-title":"Factors inducing cutaneous adverse reactions in cancer patients treated with PD-1 and PD-L1 inhibitors: A machine-learning algorithm approach","volume":"47","author":"Cho","year":"2025","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e0066520","DOI":"10.1128\/IAI.00665-20","article-title":"How Could Antibiotics, Probiotics, and Corticoids Modify Microbiota and Its Influence in Cancer Immune Checkpoint Inhibitors: A Review","volume":"89","author":"Cruellas","year":"2021","journal-title":"Infect. Immun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e184321","DOI":"10.1172\/JCI184321","article-title":"The gut microbiome and cancer response to immune checkpoint inhibitors","volume":"135","author":"Gazzaniga","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","article-title":"Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: Pooled post hoc analyses of the OAK and POPLAR trials","volume":"31","author":"Chalabi","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S1470-2045(21)00546-5","article-title":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): A propensity score-matched analysis of a single-centre, longitudinal study","volume":"22","author":"Qian","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Bacalam, C., Puscariu, I., Sur, D., and Burz, C. (2026). Impact of time-of-day on immune checkpoint inhibitor therapy in cancer patients: An up-to-date clinical review. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1837812"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/411\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:38:20Z","timestamp":1783615100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":92,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["curroncol33070411"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33070411","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]}}}